Plasminogen Activator Inhibitor-1; Human; Recombinant

Biochem/physiol Actions

Cell permeable: no

Reversible: no

Product does not compete with ATP.

Primary TargetTissue plasminogen activator (tPA) and urokinase (uPA)

≥90% by uPA assay

General description

Primary inhibitor of both tissue plasminogen activator (tPA) and urokinase (uPA). PAI-1 is synthesized by vascular epithelium and hepatocytes. Used as a marker for acute myocardial infarction and in the diagnosis of several thrombolytic disorders. Protects platelets against the inhibitory effects of plasma. Shown to have a role complimentary to that of α₂-anti-plasmin. Elevated levels are found in subjects with accelerated coronary artery disease. PP1 activity may limit the extent of metastasis, since uPA activity is a major contributory factor promoting dissolution of tumor matrix and basement membrane. May serve as an independent and strong prognosticator in breast cancer patients. Patients having elevated levels of PAI-1 in their primary tumors are more prone to relapse. Can exist either in an active inhibitory conformation or in an inactive or latent conformation. This highly purified preparation has not been exposed to denaturing conditions and has been chromatographically purified free of the inactive material.

PAI-1 is the primary inhibitor of both tissue plasminogen activator (tPA) and urokinase (uPA). PAI-1 can exist either in an active inhibitory conformation or in an inactive or latent conformation. This highly purified preparation has not been exposed to denaturing conditions and has been chromatographically purified of latent material. PAI-1 is a marker for acute myocardial infarction and several thrombolytic disorders. Protects platelets against the inhibitory effects of plasma. Reported to be an important prognostic factor in breast cancer patients. PAI-1 is highly stable when stored at or below pH 6.6.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Vaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995.Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272.Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195.Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713.Robbie, L.A., et al. 1993. Thromb. Hemost.70, 307.Lawrence, D., et al. 1989. Eur. J. Biochem.186, 523.Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders Ginsberg, D., et al. 1986. J. Clin. Invest.78, 1673.Vassalli, J.D., et al. 1985. J. Cell Biol.100, 86.

Packaging

50 µg in Plastic ampoule

Physical form

In 150 mM NaCl, 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.6.

Reconstitution

Following initial thaw, aliquot and freeze (-70°C).

Warning

Toxicity: Standard Handling (A)